Meeting
2022 ASCO Annual Meeting
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.
Authors
Joyce O'Shaughnessy
Baylor University Medical Center, Texas Oncology, US Oncology Network, Dallas, TX
Joyce O'Shaughnessy , Achim Woeckel , Barbara Pistilli , Roberto Hegg , Linda T. Vahdat , Dragica Vuina , Parisa(Fatemeh) Asad ZVK , Timothy W Smith , Julia Kim , Ian Krop
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1055)
DOI
10.1200/JCO.2022.40.16_suppl.1055
Abstract #
1055
Poster Bd #
433
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).
First Author: Dejan Juric
Poster
2021 ASCO Annual Meeting
Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm).
First Author: Hope S. Rugo
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
First Author: Dejan Juric
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
First Author: Hope S. Rugo